Press Release: Sanofi completes acquisition of Vicebio

Core Insights - Sanofi has completed the acquisition of Vicebio Ltd, enhancing its capabilities in vaccine design and development, particularly for respiratory syncytial virus (RSV) and human metapneumovirus (HMPV) through Vicebio's 'Molecular Clamp' technology [1][2] Company Overview - Sanofi is an R&D driven, AI-powered biopharma company focused on improving lives and delivering growth, with a commitment to addressing urgent healthcare challenges through innovative medicines and vaccines [3]